Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Pentaxim in South African Infants
NCT00254969Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2005
- Primary completion
- May 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b conjugate vaccine in diphtheria, Tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b infection (Hib), sponsored by Sanofi. Started Oct 2005; status: completed.
02
Drugs
diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b conjugate vaccine
03
Conditions
diphtheriaTetanuspertussispoliomyelitisHaemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT00254969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00254969.